Alan C. Foster

Alan C. Foster is currently the Vice President of Research at Otonomy. Alan has over 25 years of experience in the pharmaceutical industry, holding various leadership positions in pharmacology and neuroscience.

Foster began their career at Merck in 1984 as a Section Leader. Alan then moved to Gensia in 1992 as the Senior Director of CNS Pharmacology. In 1996, they joined Neurocrine as the Vice President of Neuroscience, and held this position for 12 years. In 2008, they joined Allergan as the Vice President of Pharmacology, where they worked for 6 years before joining Otonomy in 2014.

Foster’s extensive experience in the pharmaceutical industry has made him an expert in drug development and they are a valuable asset to Otonomy. Under their leadership, the company is making great strides in the development of new treatments for hearing loss and balance disorders.

Alan C. Foster received their Doctor of Philosophy (Ph.D.) in Neuropharmacology from the University of Southampton. Alan then completed postdoctoral research at the Maryland Psychiatric Research Center and UC Irvine. Finally, they received their Bachelor's Degree in Physiology and Biochemistry from the University of Southampton.

Their manager is David A. Weber, President & CEO. Alan C. Foster works with Carla Da Luz Boren - General Counsel and Head of Human Resources, Barbara M. Finn - Vice President, Regulatory Affairs and Quality Assurance, and Robert Michael Savel - Chief Technical Officer.